


Revumenib

Cat. No.:	HY-136175		
CAS No.:	2169919-21-3		
Molecular Formula:	C ₃₂ H ₄₇ FN ₆ O ₄ S		
Molecular Weight:	631		
Target:	Epigenetic Reader Domain		
Pathway:	Epigenetics		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	1 year
		-20°C	6 months



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 25 mg/mL (39.62 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.5848 mL	7.9239 mL	15.8479 mL
	5 mM	0.3170 mL	1.5848 mL	3.1696 mL
	10 mM	0.1585 mL	0.7924 mL	1.5848 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 4.17 mg/mL (6.61 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 4.17 mg/mL (6.61 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 4.17 mg/mL (6.61 mM); Clear solution
- Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline
Solubility: ≥ 2.5 mg/mL (3.96 mM); Clear solution
- Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (3.96 mM); Clear solution
- Add each solvent one by one: 1% DMSO >> 99% saline
Solubility: ≥ 0.5 mg/mL (0.79 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding K_i of 0.149 nM and a cell based IC_{50} of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) ^[1] .
IC_{50} & Target	Menin-MLL ^[1]
In Vivo	Revumenib (SNDX-5613) shows in vivo plasma IC_{50} of 53 nM. Revumenib treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Cancer Discov. 2022 Mar 1;12(3):792-811.
- Blood. 2023 Oct 27;blood.2023021359.
- Leukemia. 2023 Mar 28.
- iScience. 2021 Dec 25;25(1):103679.
- bioRxiv. 2023 Oct 1.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory).

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA